AEVI GENOMIC MEDICINE, INC.
AEVI GENOMIC MEDICINE, INC. (GNMX): 5 pipeline candidates · ~3 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
2.5 months
D/E -1.81 · 0% dilution
Lead: Phase 1
5 candidates
N/A
N/A
A transparent, data-derived signal for AEVI GENOMIC MEDICINE, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.6B
Cash
$2.4M
Quarterly Burn
$3.1M
Runway
2.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
Frequently asked questions
How many drug candidates are in AEVI GENOMIC MEDICINE, INC.'s pipeline?
AEVI GENOMIC MEDICINE, INC. (GNMX) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is AEVI GENOMIC MEDICINE, INC.'s lead drug candidate?
AEVI GENOMIC MEDICINE, INC.'s most advanced tracked candidate is aevi-001 (Preclinical) for ADHD.
What is AEVI GENOMIC MEDICINE, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, AEVI GENOMIC MEDICINE, INC. has approximately 2.5 months of cash runway.
What is AEVI GENOMIC MEDICINE, INC.'s market capitalization?
AEVI GENOMIC MEDICINE, INC.'s market capitalization is approximately $1.6B.
Who is the CEO of AEVI GENOMIC MEDICINE, INC.?
Pennsylvania August is the chief executive officer of AEVI GENOMIC MEDICINE, INC. (GNMX).
Get the full picture on AEVI GENOMIC MEDICINE, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.